Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFor private prescription of Mounjaro (tirzepatide) in the UK, the licensed BMI threshold is 30 or above — or 27 and above if you have at least one weight-related health condition such as high blood pressure, type 2 diabetes or high cholesterol. BMI alone never settles the question; a prescriber assesses your full clinical picture before any prescription is issued. Mounjaro is a prescription-only medicine, so that clinical assessment is a legal requirement, not a formality.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Not quite. The Mounjaro SmPC (the product's official licensed specification) sets BMI 30 as the entry point for adults seeking weight management treatment. If your BMI sits between 27 and 29.9, at least one weight-related comorbidity needs to be present: prediabetes, established type 2 diabetes, hypertension, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea and osteoarthritis are among the conditions that count. The idea is that the medicine is reserved for people whose weight is already affecting their health in a measurable way.
That said, meeting the BMI threshold is a necessary condition, not a sufficient one. A prescriber will also consider your full medical history, any medicines you currently take, and contraindications listed in the licence, a history of medullary thyroid carcinoma or MEN2, for example, rules Mounjaro out regardless of BMI. If you are currently taking other glucose-lowering medicines such as metformin, it is worth checking whether metformin can be taken alongside Mounjaro before your consultation. It is worth reading through the detail of what you need to qualify for Mounjaro beyond the number on the scale.
One thing our prescribers hear most weeks: people who assume a borderline BMI means an automatic refusal. In reality the prescriber weighs up the whole picture. Someone at BMI 28 with well-documented sleep apnoea and hypertension may be entirely appropriate; someone at BMI 32 with a contraindicated condition is not. The number opens the door; the clinical conversation decides.
Yes, and it matters. UK clinical guidance (reflected in both the NICE appraisal of tirzepatide (TA1026) and NHS England's weight-management framework) recognises that health risks associated with excess weight occur at lower BMI values in people from South Asian, Chinese, other Asian, Middle Eastern, Black African and African-Caribbean backgrounds. The adjustment is 2.5 kg/m² lower across the thresholds. In practice that means a starting cut-off of 27.5 for general weight management eligibility, and 24.5 where 27 would otherwise apply.
This is not a minor footnote. Someone from a South Asian background at BMI 28 who has hypertension may meet the adjusted criteria where they would not under the unadjusted numbers. If this applies to you, it is worth raising explicitly during your consultation, and worth checking the BMI thresholds for Mounjaro in more detail before you do.
The NHS BMI calculator acknowledges ethnic-background considerations and is a reasonable first reference point, though a formal prescriber assessment remains the authoritative step. You can use the NHS BMI calculator to check where you currently sit.
Quite significantly. NICE's appraisal (TA1026, published December 2024 and updated September 2025) recommends tirzepatide on the NHS for adults with a BMI of 35 or above and at least one weight-related comorbidity, a considerably higher bar than the licensed private threshold of 30. The comorbidities NICE specifies map to a defined list: type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea and cardiovascular disease.
NHS rollout is also phased. From June 2025, NHS access opened for people with BMI 40 or above plus four or more of those five conditions. A second cohort, covering BMI 35–39.9 with four or more conditions, became eligible from June 2026. Further cohorts are planned through to 2027. Meeting the BMI criteria for an NHS prescription still does not guarantee access, availability depends on your GP practice's participation in the scheme and whether your integrated care board has activated the relevant services in your area.
For people who do not meet NHS thresholds, or who prefer not to wait, private treatment through a regulated online pharmacy is the legal alternative. If you want to understand the full eligibility picture, the breakdown of what BMI you need for Mounjaro covers both routes side by side. For context on what private treatment costs, the Mounjaro pricing page sets out what is included.
The honest answer: a prescriber cannot issue a Mounjaro prescription outside the licensed criteria. If your BMI is 29.5 with no qualifying conditions, that conversation ends at the assessment stage. This protects you, prescribing outside a medicine's licence is a significant clinical and regulatory matter, and any service willing to skip it is worth walking away from.
There are things worth checking, though. First, whether any comorbidity brings you into the 27+ bracket, conditions sometimes go unrecorded rather than absent. Second, whether your BMI calculation is current; weight fluctuates and measurements taken months apart can differ meaningfully. Third, whether the ethnic-background adjustment applies to you. A prescriber will work through all of this as part of a proper assessment.
If Mounjaro is not the right fit at this point, it may still be worth exploring what other options exist. The weight-loss treatment overview covers the full range of licensed options available through nume, and the Mounjaro treatment page sets out what the medicine involves for those who do meet the criteria. Speak to our prescribers through a free consultation to get a clear answer for your specific situation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.